Colibri Heart Valve Strengthens Patent Portfolio with Receipt of 12th Transcatheter Heart Valve (THV) Patent

BROOMFIELD, CO, Colibri Heart Valve LLC, a privately held emerging medical device company, has received an Issue Notification from the U.S. Patent and Trademark Office regarding the forthcoming granting of U.S. Patent No. 9,125,739 (the "'739 Patent") titled, "Percutaneous Replacement Heart Valve and a Delivery and Implantation System."  This will be Colibri's 12^th allowed/granted patent and will issue on September 8, 2015.  The '739 Patent is a utility patent directed to an assembly that includes a transcatheter heart valve with a tubular structure away from its central portion that flares at both ends.  The assembly further includes a pusher member and a delivery sheath.  The associated patent application (14/253,650) has priority claims with content dating back to January 4, 2002. It is expected that the '739 Patent will provide Colibri with broad protection for the claimed assembly through January 4, 2022.  This patent issuance represents the 5^th Colibri THV patent allowed/granted in 2015.

"Colibri has invested heavily in maximizing its intellectual property footprint, which has been significantly bolstered with the addition of this patent," stated Joseph B. Horn, Colibri's president and chief executive officer. "This soon-to-issue patent covers a percutaneous replacement heart valve and a delivery and implantation system with a priority date of 2002 that is both early and meaningful in the transcatheter heart valve market."

With the strengthened patent portfolio, Colibri is positioned to accelerate development of a self-expanding heart valve program to complement its clinical-stage disruptive balloon expandable heart valve technology.  The addition of a self-expanding program positions Colibri to be the only company with both intellectual property and technology to develop pre-packaged, ready-for-use, balloon and self-expanding transcatheter heart valve technology for aortic, mitral, and pulmonary applications. 

Source: Colibri Heart Valve LLC